ONWARD Medical

🎉 Today marks a truly historic moment – not just for our company, but for the entire spinal cord injury (SCI) community.  After more than a decade of pioneering research and unwavering dedication, we have received FDA De Novo classification and authorization to market the ARC-EX® System, the world's first non-invasive spinal cord stimulation system proven to improve strength and sensation after chronic SCI. 💫 Here are some key highlights of the ARC-EX System: ⭐️ 90% of clinical trial participants showed improved strength or function* in clinical trials ⭐️ Benefits seen up to 34 years post-injury* in clinical trials ⭐️ Named a Time Magazine Best Invention of 2024 For the first time ever, there is an approved therapy to improve hand strength and sensation for people with SCI. This recognition is particularly meaningful because it acknowledges more than just technological innovation – it validates the benefits of this therapy for the millions of people worldwide who dream of regaining movement and independence after SCI. We thank the entire SCI Community for supporting us in our journey to develop and introduce this breakthrough technology. Together, we are not just developing devices; we are reshaping what is possible after spinal cord injury. 🚀 🔗 For more details, read our press release (link in comments).  *Moritz, Chet, et al. “Non-invasive spinal cord stimulation for arm and hand function in chronic tetraplegia: a safety and efficacy trial.” Nature Medicine. 2024. #EmpoweringMovement #SCI #MedicalBreakthrough #Innovation  Note: The ARC-EX System is intended to deliver programmed, transcutaneous electrical spinal cord stimulation in conjunction with functional task practice in the clinic to improve hand sensation and strength in individuals between 18 and 75 years old that present with a chronic, non-progressive neurological deficit resulting from an incomplete spinal cord injury (C2-C8 inclusive). Please note that all other ONWARD Medical devices and therapies, including ARC-IM®, ARC-BCI®, and ARC Therapy™ with brain-computer interfaces (BCIs), are investigational and not commercially approved. Patient testimonials reflect individual experiences and outcomes, which may vary. Please review the full product label and clinical study data. 

📣 This morning, Good Morning America reported on a “a new device just cleared by the FDA that could be a game-changer for the 300,000 Americans with spinal cord injury.” 📺 That device is ARC-EX. ABC News correspondent Will Reeve, son of Christopher Reeve, called ARC-EX a “breakthrough for people living with spinal cord injury,” and invoked his deep ties to the spinal cord injury (SCI) community by providing context on this historic event. ⭐️ “Progress in spinal cord injury research is usually measured in decades,” said Reeve. “So this is a long time coming. And to be able to say this is here and getting out to people who need it is a big moment.” Will interviewed Up-LIFT trial principal investigator and University of Washington professor and neuroscientist Chet Moritz about our technology. The story centered around trial participant Jessie Owen, whose life transformed in every way from this therapy. 🙏 Thank you, GMA and ABC News for shining a light on the longstanding unmet needs of the SCI Community and showing how a device like ARC-EX can, in Will’s words, offer “a new level of freedom and hope.” As Jessie told Will – “The future of spinal cord injury treatment is being written right now. This is the moment. And this provides the hope and the stepping stone to start that journey.” ✨ #EmpoweringMovement #SCI #GMA #Hope #Freedom Note: The ARC-EX System is intended to deliver programmed, transcutaneous electrical spinal cord stimulation in conjunction with functional task practice in the clinic to improve hand sensation and strength in individuals between 18 and 75 years old that present with a chronic, non-progressive neurological deficit resulting from an incomplete spinal cord injury (C2-C8 inclusive). Please note that all other ONWARD Medical devices and therapies, including ARC-IM®, ARC-BCI®, and ARC Therapy™ with brain-computer interfaces (BCIs), are investigational and not commercially approved.  Patient testimonials reflect individual experiences and outcomes, which may vary. Please review the full product label and clinical study data.

✨ Thank you, Stephanie Price of NR Times, for including us in this year’s NR Times Yearbook! We appreciate your deep-dive interview with our CEO Dave Marver about our breakthrough solutions, clinical developments, and upcoming plans.    We are honored to be recognized as a leader in #neurorehab and appreciate NR Times’ commitment to improve the lives of those with brain and spinal cord injuries through detailed reporting and thoughtful education.    #EmpoweringMovement #SCI #NRTimesYearbook   Note: All ONWARD® Medical devices and therapies, including but not limited to ARC-IM®, ARC-EX®, ARC-BCI™, and ARC Therapy™, alone or in combination with a brain-computer interface (BCI), are investigational and not available for commercial use.

🛎️ We are delighted to share that we have been recognized as a global leader in corporate sustainability!  We have received a silver medal from EcoVadis, the world’s largest provider of business sustainability ratings. The evaluation process is rigorous, and the assessment is based around four core themes: Environment, Labor & Human Rights, Ethics, and Sustainable Procurement. More than 130,000 companies globally have been rated by EcoVadis.    🏆 The award places us in the top 15% of companies that EcoVadis assessed in the last year. This recognition means a lot to us. We care deeply about our environmental, social impact, and our commitment to sustainable business practices. Our sustainability strategy is centered on five core principles that support nine United Nations Sustainable Development Goals:  ⭐️ Minimizing our environmental footprint  ⭐️ Innovating for the underserved  ⭐️ Partnering with patient groups  ⭐️ Maintaining high ethical standards As we celebrate this achievement, we remain focused on our journey toward an even more sustainable future. 🌏    🔗 Read more details in our press release. ⬇️    #EmpoweringMovement #SCI #Sustainability #UNSDGS    Note: All ONWARD® Medical devices and therapies, including but not limited to ARC-IM®, ARC-EX®, ARC-BCI™, and ARC Therapy™, alone or in combination with a brain-computer interface (BCI), are investigational and not available for commercial use. 

🎉 Congratulations to our co-founders and research partners, G. Courtine and Jocelyne Bloch of .NeuroRestore, for their recent Nature Medicine publication on deep brain stimulation and its potential to help people with paralysis, which has been highlighted by media outlets like the The Economist. We look forward to learning more about this exciting new frontier! 💡 #EmpoweringMovement #SCI #DBS Note: All ONWARD® Medical devices and therapies, including but not limited to ARC-IM®, ARC-EX®, ARC-BCI™, and ARC Therapy™, alone or in combination with a brain-computer interface (BCI), are investigational and not available for commercial use.

💫 Thank you, Martin Egan of CGTN, for your thoughtful story on the therapies we have developed to help people with spinal cord injury (SCI) move again and live more independently.     🎤 Martin interviewed our CEO Dave Marver and SCI Ventures Founding Managing Director Adrien Cohen at Web Summit in Portugal last month. The pair was featured at the prestigious tech conference in an on-stage interview with Katherine Ward of Global News Canada about the critical need for investment in breakthrough technologies for the SCI Community.     📺 The CGTN story demonstrates the value of raising awareness of the unmet needs of those with SCI, and Cohen’s aspirational vision that with the right investment accelerating innovation, “there’s a real possibility that this generation will be the first one to recover from paralysis.” ✨    #EmpoweringMovement #SCI #CGTN #WebSummit2024    Note: All ONWARD® Medical devices and therapies, including but not limited to ARC-IM®, ARC-EX®, ARC-BCI™, and ARC Therapy™, alone or in combination with a brain-computer interface (BCI), are investigational and not available for commercial use.   

✨ Today is the International Day of Persons with Disabilities (IDPD).     The United Nations began this day of observance five years ago to ensure that people with disabilities in conflict situations have access to justice, services, and humanitarian aid.     The theme for #IDPD2024 is “Amplifying the leadership of persons with disabilities for an inclusive and sustainable future.”     The UN will commemorate #IDPD2024 with a series of events around the world, including a main event at UN headquarters in New York. 🇺🇳    The UN’s key goals include:    ⭐️ Empowering people with disabilities with leadership and decision-making opportunities.  ⭐️ Promoting awareness and inclusion of persons with disabilities in all aspects of society.  ⭐️ Celebrating the achievements of those with disabilities.     We honor persons with disabilities, which include the seven million people with spinal cord injury (SCI) worldwide, for the day-to-day challenges and unmet needs they face. We hope this day brings empowerment, independence, and hope. 🙏    #EmpoweringMovement #SCI #UN #IDPD2024    Note: All ONWARD® Medical devices and therapies, including but not limited to ARC-IM®, ARC-EX®, ARC-BCI™, and ARC Therapy™, alone or in combination with a brain-computer interface (BCI), are investigational and not available for commercial use.  https://lnkd.in/dkK3MGF

🍁Giving thanks to a year filled with exciting milestones, clinical developments, and progress towards bringing our therapies to those with spinal cord injury (SCI). We are grateful for our partners, advocates, and the SCI Community for inspiring our journey. Happy Thanksgiving! 🦃 #EmpoweringMovement #SCI #Gratitude #Thanksgiving Note: All ONWARD® Medical devices and therapies, including but not limited to ARC-IM®, ARC-EX®, ARC-BCI™, and ARC Therapy™, alone or in combination with a brain-computer interface (BCI), are investigational and not available for commercial use. 

Yesterday, we provided investors with a Q3 2024 update and year-to-date achievements, reaffirming our 2024 strategic priorities.  Our top focus remains preparing for commercialization of the ARC-EX System--pending FDA review--and we look forward to bringing ARC-EX to the Spinal Cord Injury (SCI) Community in the US later this year.*  Here are more ONWARD Medical accomplishments from the last several months:  ✅ Secured €50M in funding with cornerstone investment from Ottobock, now our largest strategic investor ✅ Signed an exclusive license for WIMAGINE® Brain Computer Interface (BCI) technology from Commissariat a l'Energie Atomique et aux Energies Alternatives to be commercialized with our ARC-BCI System  ✅ Announced former Medtronic President Rob ten Hoedt as incoming Board Chairman  ✅ ARC-EX System named a TIME Magazine Best Invention of 2024 ✅ Received $1.1 million grant to expand ARC-BCI feasibility research from the Christopher & Dana Reeve Foundation ✅ On track for first commercial launch in Q4 2024  Check out a recording of our Q3 Update Webcast at the link in comments. 🔗 As we approach the close of 2024, we are energized by the prospect of delivering our groundbreaking therapies to the SCI Community to advance our mission of restoring movement, function, and independence to people with SCI. ✨ #EmpoweringMovement #SCI #StrategicPriorities *All ONWARD Medical devices and therapies, including but not limited to ARC-IM®, ARC-EX®, ARC-BCI™, and ARC Therapy™, alone or in combination with a brain-computer interface (BCI), are investigational and not available for commercial use. 

✨ Thank you, Web Summit, the world's premier tech conference, for sparking a powerful conversation about transforming lives through technology. Our CEO Dave Marver and Adrien Cohen of SCI Ventures took the stage last week to explore a crucial question: How can smart investment accelerate breakthrough therapies for spinal cord injury (SCI)? The pair spoke about the critical need for investment to fuel innovative solutions for the SCI Community.    🎤 Thank you to Katherine Ward of Global News Canada for moderating "Solving Paralysis, One Investment at a Time" and diving deep into this vital conversation.    Congratulations, Web Summit, for a successful gathering of innovators, financiers, and changemakers...and for showing us what’s possible when you invest in the future. 💫    #EmpoweringMovement #SCI #WebSummit #Innovation   Note: All ONWARD® Medical devices and therapies, including but not limited to ARC-IM®, ARC-EX®, ARC-BCI™, and ARC Therapy™, alone or in combination with a brain-computer interface (BCI), are investigational and not available for commercial use.